ライフサイエンスコーパス: RSV vaccine

1 ion of G and F would be desirable for a live RSV vaccine.

2 candidate for a live attenuated recombinant RSV vaccine.

3 which is the major target population for an RSV vaccine.

4 RSV season: nirsevimab and Pfizer's maternal RSV vaccine.

5 fection may, however, impact responses to an RSV vaccine.

6 significant advance in the development of an RSV vaccine.

7 the safety and efficacy of a live attenuated RSV vaccine.

8 ecades of RSV research, there is no licensed RSV vaccine.

9 ould be considered when designing a vectored RSV vaccine.

10 lowing vaccination with formalin-inactivated RSV vaccine.

11 tant candidate for inclusion in an effective RSV vaccine.

12 he over 4-decade-long quest for a successful RSV vaccine.

13 rove the safety and long-term efficacy of an RSV vaccine.

14 ren enrolled in studies of 4 live-attenuated RSV vaccines.

15 ed in vaccine-enhanced disease with previous RSV vaccines.

16 expression with the aim of generating novel RSV vaccines.

17 important for the development of attenuated RSV vaccines.

18 ng 37 1-2-month-old infants-a target age for RSV vaccines.

19 pectively, were evaluated as live-attenuated RSV vaccines.

20 eeded to optimize the safety and efficacy of RSV vaccines.

21 e the risk of enhanced disease with non-live RSV vaccines.

22 Currently, there are no FDA-approved RSV vaccines.

23 ay be a mechanism of protection for maternal RSV vaccines.

24 nowledge and attitudes about RSV disease and RSV vaccines.

25 There currently are no FDA-approved RSV vaccines.

26 of the potential impact of the new available RSV vaccines.

27 us to assess the potential impact of future RSV vaccines.

28 ntribute to the design of broadly protective RSV vaccines.

29 V pathogenesis and to assess the efficacy of RSV vaccines.

30 ng such a mutation in future live attenuated RSV vaccines.

31 ll be important in the future development of RSV vaccines.

32 be useful biomarkers of attenuation for live RSV vaccines.

33 ds an effective respiratory syncytial virus (RSV) vaccine.

34 We evaluated the experimental RSV vaccine, Ad26.RSV.preF, a replication-incompetent ad

35 munity induced by the recombinant adenoviral RSV vaccine administered by use of an intramuscular prim

36 ndrome were diagnosed per 1 000 000 doses of RSV vaccine administered.

37 ted a single dose of BLB201, a PIV5-vectored RSV vaccine administrated via intranasal route, for safe

38 RSV vaccine and antibody strategies are likely to be cos

39 Coadministration of an RSV vaccine and influenza vaccine could be a benefit, re

40 control design was used to estimate maternal RSV vaccine and nirsevimab effectiveness.

41 lance study, during 2024-2025, both maternal RSV vaccine and nirsevimab were estimated to be effectiv

42 ction was not significantly different in the RSV vaccine and placebo groups.

43 outlining evidence for safety evaluation of RSV vaccines and a framework for understanding disease e

44 ganization and may aid in the development of RSV vaccines and anti-viral targets.

45 e important in the evaluation and use of new RSV vaccines and antivirals.

46 mportant target group for the development of RSV vaccines and antivirals.

47 the disease-enhancing potential of candidate RSV vaccines and better understand enhanced disease.

48 logy of RSV and for timing the use of future RSV vaccines and immunoprophylaxis in low- and middle-in

49 spiratory syncytial virus (RSV), and several RSV vaccines and monoclonal antibodies currently in clin

50 ubstantial efforts have been made to develop RSV vaccines and vaccine-like monoclonal antibodies to p

51 f protection of respiratory syncytial virus (RSV) vaccines and monoclonal antibodies (mAbs) is virus

52 ure-guided design of the RSV G protein as an RSV vaccine antigen.

53 pre-F conformation and support its use as an RSV vaccine antigen.

54 el that was used to estimate the EJP, for an RSV vaccine applying different willingness-to-pay (WTP)

55 er adults from GlaxoSmithKline was the first RSV vaccine approved by the US Food and Drug Administrat

56 mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated l

57 RSV vaccines are available, however there is still signi

58 us (RSV) is a significant human pathogen, no RSV vaccines are available.

59 However, no RSV vaccines are available.

60 the safety and immunogenicity data of these RSV vaccines are encouraging, low rates of infection mak

61 Experimental live attenuated RSV vaccines are grown in Vero cells, but during product

62 Rationally designed live-attenuated RSV vaccines are in clinical development.Objectives: Dev

63 Several promising live-attenuated RSV vaccines are in development.

64 l but nonprotective immunity on responses to RSV vaccines are not clear.

65 that ablation of the CX3C motif or sG in an RSV vaccine, as has been suggested previously, would be

66 Given recent RSV vaccine authorizations, data on groups at highest ri

67 Although there is no safe and effective RSV vaccine available, significant progress has been rec

68 potential to be developed as a prophylactic RSV vaccine based on innate, cellular, and humoral immun

69 mbinant subunit respiratory syncytial virus (RSV) vaccines based on prefusion RSV F glycoproteins for

70 ldren who received minimally attenuated live RSV vaccines but not in children who received highly att

71 We have generated an epitope-specific RSV vaccine by grafting a neutralizing epitope (F-epitop

72 a novel strategy to attenuate a recombinant RSV vaccine by incorporating a low-fusion, subgroup B F

73 d development of this promising nanoparticle RSV vaccine candidate and establish computationally desi

74 icate that RSVNanoVax represents a promising RSV vaccine candidate capable of providing long-term pro

75 mphasize the need to investigate a pediatric RSV vaccine candidate carefully for priming of ERD over

76 /404 parent virus, making it a promising new RSV vaccine candidate created by use of reverse genetics

77 ) to produce the recombinant live-attenuated RSV vaccine candidate DeltaNS2/Delta1313.

78 ed to evaluate suboptimal dosing for any new RSV vaccine candidate developed for seronegative infants

79 re underscore the need to evaluate a nonlive RSV vaccine candidate during preclinical development ove

80 upports the development of ChAd155-RSV as an RSV vaccine candidate for infants.

81 In cotton rats, this RSV vaccine candidate is highly attenuated at a dose of

82 ve reported that a virus-like particle (VLP) RSV vaccine candidate stimulated, in mice, robust, prote

83 This provides an improved vectored RSV vaccine candidate suitable for pediatric clinical ev

84 Overall, this report describes a potential RSV vaccine candidate that merits further evaluation in

85 comparable to that of MEDI-559, a promising RSV vaccine candidate that presently is in clinical tria

86 rA2cp248/404/1030 Delta SH is the first RSV vaccine candidate to be sufficiently attenuated in y

87 ed version of this promising live-attenuated RSV vaccine candidate, this study demonstrated the prope

88 tential of virus-like particles (VLPs) as an RSV vaccine candidate.

89 represents a promising novel live-attenuated RSV vaccine candidate.

90 efusion RSV F nanovaccine is a promising new RSV vaccine candidate.

91 m of the RSV F protein represent a promising RSV vaccine candidate.

92 Ps has the potential to produce a successful RSV vaccine candidate.

93 ur data indicated that PIV5/F is a promising RSV vaccine candidate.IMPORTANCE A safe and efficacious

94 Currently, several RSV vaccine candidates are under development to target d

95 We designed new live attenuated RSV vaccine candidates by codon-pair deoptimization (CPD

96 ron- alpha / beta response, was deleted from RSV vaccine candidates by use of reverse genetics.

97 e of RSV in bacterial OM and the efficacy of RSV vaccine candidates designed to provide mucosal and c

98 tenuating mutations in new, live recombinant RSV vaccine candidates for both pediatric and elderly po

99 d Abs can be readily induced in mice by live RSV vaccine candidates in the presence of physiologic le

100 erall, mucosally delivered rVSV-vector-based RSV vaccine candidates induce protective immunity and th

101 genicity and efficacy of two live attenuated RSV vaccine candidates of different level of attenuation

102 However, NS2-deleted RSV vaccine candidates rendered RSV overattenuated or po

103 loped two parainfluenza virus 5 (PIV5)-based RSV vaccine candidates that protect mice against RSV cha

104 Most importantly, we found that PIV5-based RSV vaccine candidates were efficacious in preventing lo

105 Three NS2 gene-deleted RSV vaccine candidates were studied: rA2cp Delta NS2, rA

106 Two live attenuated, recombinantly derived RSV vaccine candidates, rA2cp248/404 Delta SH and rA2cp2

107 in mice, in contrast to other nonreplicating RSV vaccine candidates.

108 lusion in future live attenuated recombinant RSV vaccine candidates.

109 routinely used to evaluate the safety of new RSV vaccine candidates.

110 oing obstacle for the development of nonlive RSV vaccine candidates.

111 ed into foreign VLP systems to generate anti-RSV vaccine candidates.

112 optimized human respiratory syncytial virus (RSV) vaccine candidates in the context of strong selecti

113 ational chimpanzee-derived adenoviral vector RSV vaccine (ChAd155-RSV, expressing RSV F, N, and M2-1)

114 RSV vaccine clinical trials reported higher frequencies

115 We have developed a novel RSV vaccine composed of a prefusion-stabilized variant o

116 binant chimeric respiratory syncytial virus (RSV) vaccine consisting of the extramembrane domains of

117 ions: Rapid development of a live-attenuated RSV vaccine could contribute substantially to reducing t

118 A future RSV vaccine could substantially reduce unnecessary antib

119 n from reinfection, and there is no licensed RSV vaccine currently available.

120 act disease in older adults, but no licensed RSV vaccine currently exists.

121 Considering that most RSV vaccines currently being developed aim at inducing (

122 Live RSV vaccine D46/NS2/N/DeltaM2-2-HindIII, attenuated by d

123 sults have important implications for future RSV vaccine design, suggesting that enhancing a Th1 resp

124 t IFN-alpha is a promising target for future RSV vaccine design.

125 cell responses is important to consider for RSV vaccines designed for young infants.

126 A formalin-inactivated RSV vaccine developed in the 1960s not only showed a com

127 These events hampered RSV vaccine development for decades.

128 Most ongoing efforts in RSV vaccine development have focused on the viral fusion

129 The difficulties involved in RSV vaccine development were recognized in an early vacc

130 This review discusses the storied history of RSV vaccine development, immunological lessons learned a

131 dels has been one of the major challenges to RSV vaccine development.

132 sequently focus on the promising pipeline of RSV vaccine development.

133 Respiratory syncytial virus (RSV) vaccine development for direct protection of young

134 Receipt of 1 RSV vaccine dose at least 14 days before illness onset.

135 transplant recipients including questions of RSV vaccine effectiveness and safety, inequities in dise

136 and infants younger than 6 months, maternal RSV vaccine effectiveness was 64% (95% CI, 37%-79%) agai

137 To estimate maternal RSV vaccine effectiveness, the exposure was maternal RSV

138 inform selection of clinical end points for RSV vaccine efficacy trials.

139 Among recipients of "more promising" RSV vaccines, efficacy against RSV-MAARI was 67% (95% co

140 talized adults, knowledge of RSV disease and RSV vaccine eligibility was low.

141 nogenicity of an adenovirus serotype 5-based RSV vaccine encoding the fusion (F) protein (Ad5.RSV-F)

142 26 vector-based respiratory syncytial virus (RSV) vaccine encoding a prefusion conformation-stabilize

143 These measures of RSV vaccine-enhanced disease are dependent upon STAT4.

144 RSV vaccine-enhanced disease can be mimicked in BALB/c m

145 ever, the role of FasL in the development of RSV vaccine-enhanced disease has not been elucidated.

146 after RSV challenge that closely mimics the RSV vaccine-enhanced disease observed in humans.

147 The underlying causes of RSV vaccine-enhanced disease remain poorly understood.

148 effector CD4 T cells and the development of RSV vaccine-enhanced disease.

149 s elicited by RSV G are not the basis for FI-RSV vaccine-enhanced disease.

150 understanding the mechanisms attributable to RSV vaccine-enhanced disease.

151 pulmonary eosinophil response related to FI-RSV vaccine-enhanced disease.

152 otection and are not solely the basis for FI-RSV vaccine-enhanced illness.

153 on grants these cells the ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia.

154 pathogenesis of respiratory syncytial virus (RSV) vaccine-enhanced disease in the mouse model.

155 The PIV3-vectored RSV vaccines evaluated here further underscore the utili

156 evel observed in adults among all intranasal RSV vaccines evaluated in humans.

157 Presently, no safe and efficacious RSV vaccine exists; however, advances in our understandi

158 ously vaccinated with a formalin-inactivated RSV vaccine experienced enhanced morbidity and mortality

159 lin-inactivated respiratory syncytial virus (RSV) vaccine experienced enhanced disease and exhibited

160 -inactivated respiratory syncytial virus (FI-RSV) vaccine experienced enhanced respiratory disease, i

161 SV, an investigational chimpanzee adenovirus-RSV vaccine expressing 3 proteins (fusion, nucleoprotein

162 s (a formalin-inactivated, alum-precipitated RSV vaccine [FI-RSV] given intramuscularly and live RSV

163 ity estimates and inform policy decisions on RSV vaccine financing and prioritization at the global a

164 An RSV vaccine for infants is still not available.

165 A live attenuated RSV vaccine for the youngest infant will use cpts-248/40

166 ly great enough to justify development of an RSV vaccine for use in this group.

167 V vaccine in the elderly might differ from a RSV vaccine for young children.

168 is incident precluded development of subunit RSV vaccines for infants for over 30 years, because the

169 advancements have led to the licensure of 3 RSV vaccines for older adults and pregnant people.

170 d by the subsequent FDA approval of Pfizer's RSV vaccines for older adults and pregnant women.

171 We modelled the coverages of RSV vaccines for older people (age >=60 years) and pregn

172 el itself and to safe development of nonlive RSV vaccines for seronegative infants and children.

173 The respiratory syncytial virus (RSV) vaccine for older adults from GlaxoSmithKline was t

174 ended the first respiratory syncytial virus (RSV) vaccines for adults aged 60 years and older using s

175 Respiratory syncytial virus (RSV) vaccines for adults aged 60 years or older became a

176 Neither RSV vaccine formulation had an effect on the humoral res

177 enza vaccine given concomitantly with 1 of 2 RSV vaccine formulations in persons > or =65 years old w

178 ants aged 60 years or older who received the RSV vaccine from July 1, 2023, to June 30, 2024 were inc

179 ting design and distribution of a successful RSV vaccine globally.

180 ed with a nonlive, formalin-inactivated (FI)-RSV vaccine has been associated with serious enhanced re

181 use of illness and death in older adults, no RSV vaccine has been licensed.

182 a serious human respiratory pathogen, but no RSV vaccine has been licensed.

183 the virus was isolated in 1955, an effective RSV vaccine has not been developed, and the only license

184 nd most efforts to develop a live attenuated RSV vaccine have focused on strain A2 or other subgroup

185 Trials of RSV vaccines have recently shown excellent safety and ef

186 The COVID-19 pandemic and new RSV vaccines highlight the importance of a broader appro

187 es, supporting its further development as an RSV vaccine immunogen.

188 -independent candidate for a next-generation RSV vaccine immunogen.

189 the safety and efficacy of a live attenuated RSV vaccine.IMPORTANCE RSV binds to the corresponding ch

190 he immunologic requirements for a successful RSV vaccine in the elderly might differ from a RSV vacci

191 of the cost-effectiveness of a hypothetical RSV vaccine in the Netherlands and the United Kingdom.

192 amined the genetic stability of a PIV5-based RSV vaccine in vitro and in vivo We found that insertion

193 from seven phase 1 trials of live-attenuated RSV vaccines in 6- to 24-month-old children (n = 239).Me

194 ant protection), nirsevimab for infants, and RSV vaccines in adults who were 60 years of age or older

195 s the study of mucosal response to candidate RSV vaccines in frail elderly populations.

196 As countries debate whether to include RSV vaccines in maternal vaccination programs, which are

197 esults suggest that these VLPs are effective RSV vaccines in mice, in contrast to other nonreplicatin

198 , while achieving similar titres to approved RSV vaccines in mice.

199 -inactivated respiratory syncytial virus (FI-RSV) vaccine in 1966-1967 caused disastrous worsening of

200 ure of maternal respiratory syncytial virus (RSV) vaccines in Europe and the United States, data are

201 Here we show that current RSV vaccines induce undesirable anti-foldon antibodies i

202 need to be identified and addressed prior to RSV vaccine introduction to guide the measurement of imp

203 ence of RSV disease and the impact of future RSV vaccine introduction.

204 iated hospitalizations among adults prior to RSV vaccine introduction.

205 serious disease in infants, and no approved RSV vaccine is available for infants.

206 No RSV vaccine is currently available.

207 An RSV vaccine is not yet available.

208 A live attenuated RSV vaccine is one of the most promising vaccine strateg

209 Vaccines are not available, and an RSV vaccine is particularly needed.

210 s and the elderly, but no safe and effective RSV vaccine is yet available.

211 nd young children, but no safe and effective RSV vaccine is yet available.

212 nactivated (FI) respiratory syncytial virus (RSV) vaccine led to exacerbated disease including pulmon

213 An effective RSV vaccine may offer benefits for these adults.

214 ction of neutralizing serum antibody with an RSV vaccine may potentially reduce disease severity in a

215 Future maternal RSV vaccines may have added benefit in areas with high H

216 Future maternal RSV vaccines may have added benefit in high HIV prevalen

217 A live RSV vaccine might similarly decrease the risk of enhance

218 A lipid nanoparticle-encapsulated mRNA-based RSV vaccine (mRNA-1345) that encodes the membrane-anchor

219 An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV pref

220 l evaluates safety and immunogenicity of the RSV vaccine, mRNA-1345, in adults aged 18-59 years at in

221 An mRNA-based respiratory syncytial virus (RSV) vaccine, mRNA-1345, is under clinical investigation

222 rly worldwide; however, there is no licensed RSV vaccine or effective drug treatment available.

223 An effective maternal RSV vaccine or monoclonal antibody could have a substant

224 78.5%) were unsure if they were eligible for RSV vaccine or thought they were not.

225 in humans that ultimately lead to successful RSV vaccines or therapeutics.

226 need, we have failed to produce efficacious RSV vaccines or therapeutics.

227 -inactivated respiratory syncytial virus (FI-RSV) vaccine or RSV G glycoprotein results in enhanced p

228 t likely to receive vaccine to inform future RSV vaccine outreach efforts.

229 lin-inactivated respiratory syncytial virus (RSV) vaccine preparations have been shown to cause enhan

230 ly improve the performance of live pediatric RSV vaccines presently being developed.

231 challenges associated with a live attenuated RSV vaccine, providing, against the two leading viral ag

232 With RSV vaccines reaching the final stages of development, a

233 Analyses were stratified by timing of RSV vaccine receipt (same vs prior season) relative to i

234 a priori as possible factors associated with RSV vaccine receipt and were entered into a modified Poi

235 e clustering, to assess for association with RSV vaccine receipt.

236 Overall, 48.5% and 30.9% of RSV vaccine recipients reported local and systemic solic

237 years, demonstrating a need for unequivocal RSV vaccine recommendations in SNF and AL residents.

238 cohort during the 16 months before the first RSV vaccine recommendations, RSV disease was less common

239 coverage comparisons linking to the national RSV vaccine register.

240 e and effective respiratory syncytial virus (RSV) vaccines remain elusive.

241 The development of a safe and efficacious RSV vaccine remains an important goal.

242 ive research efforts, a safe and efficacious RSV vaccine remains elusive.

243 and efficacious respiratory syncytial virus (RSV) vaccine remains elusive.

244 The lack of a safe and effective RSV vaccine represents a major unmet medical need.

245 zed with RSV before the 2023 introduction of RSV vaccines, RSV was associated with substantial burden

246 investigational respiratory syncytial virus (RSV) vaccine, RSV prefusion protein F3 (RSVPreF3), was c

247 n is restricted to the respiratory tract, an RSV vaccine should elicit mucosal immunity at upper and

248 Although it is widely agreed that an RSV vaccine should induce both mucosal and systemic anti

249 To test the hypothesis that FI-RSV vaccine stimulates the production of enhancing antib

250 ever, it has been a challenge to identify an RSV vaccine strain that has an optimal balance between a

251 A number of live attenuated RSV vaccine strains have been developed in which the sma

252 ction may offer a new, safe, and efficacious RSV vaccine strategy.

253 tegy for maternal immunization and for other RSV vaccine target populations such as older adults.

254 critical step in the development of nonlive RSV vaccines targeting RSV-naive children and infants.

255 fants were lower with the candidate maternal RSV vaccine than with placebo but that the risk of prete

256 esign yielded a genetically stable candidate RSV vaccine that is attenuated yet immunogenic in RSV-se

257 udies are being conducted to identify a live RSV vaccine that is slightly more attenuated and less tr

258 s, this study indicates that live attenuated RSV vaccines that are immunogenic and phenotypically sta

259 The results suggest that RSV vaccines that induce antibodies that block G protein

260 nactivated (FI) respiratory syncytial virus (RSV) vaccine that is characterized by increased viral re

261 live attenuated respiratory syncytial virus (RSV) vaccines that contain combinations of known attenua

262 live attenuated respiratory syncytial virus (RSV) vaccines that have advanced to clinical trials have

263 r results suggest that the failure of the FI-RSV vaccine to induce a CD8 T cell response may have con

264 , placebo-controlled trial, administering an RSV vaccine to pregnant mothers reduced antimicrobial pr

265 There are no licensed RSV vaccines to date.

266 Low maternal RSV vaccine uptake precluded assessment of effectiveness

267 AND PARTICIPANTS: During the first season of RSV vaccine use from October 1, 2023, to April 30, 2024,

268 is an effective viral vector for delivering RSV vaccine, warranting further development as a novel i

269 The RSV vaccine was immunogenic but did not protect older ad

270 on-based, propensity-matched study, we found RSV vaccine was not associated with increased risk of ne

271 Development of an RSV vaccine was stymied when a clinical trial using a fo

272 The replication of the RSV vaccines was suppressed in the lower, but not the up

273 nactivated (FI) respiratory syncytial virus (RSV) vaccine, we studied the pulmonary inflammatory resp

274 response to influenza vaccination, and both RSV vaccines were well tolerated by 1169 participants.

275 2023, the first respiratory syncytial virus (RSV) vaccines were recommended for US adults 60 years or

276 A respiratory syncytial virus (RSV) vaccine will need to be administered by 1 mo of age

277 for implementation of a safe and immunogenic RSV vaccine within the context of global health and with

278 An ideal RSV vaccine would be effective for neonates, but the imm

279 An effective RSV vaccine would likely substantially reduce the burden

280 The blocking of cleavage should improve RSV vaccine yield, consequently reducing production cost